Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells.
Swierczek S, Nausova J, Jelinek J, Liu E, Roda P, Kucerova J, Jarosova M, Urbankova H, Indrak K, Prchal JT, Divoky V. Swierczek S, et al. Among authors: indrak k. Am J Hematol. 2013 Feb;88(2):157-8. doi: 10.1002/ajh.23362. Epub 2012 Dec 24. Am J Hematol. 2013. PMID: 23280542 Free PMC article.
Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.
Holzerová M, Faber E, Veselovská J, Urbánková H, Balcárková J, Rozmanová S, Voglová J, Muzík J, Chroust K, Indrák K, Jarosová M; CAMELIA-Chronic Myeloid Leukaemia Project. Holzerová M, et al. Among authors: indrak k. Cancer Genet Cytogenet. 2009 May;191(1):1-9. doi: 10.1016/j.cancergencyto.2008.12.013. Cancer Genet Cytogenet. 2009. PMID: 19389502
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response.
Faber E, Friedecký D, Micová K, Divoká M, Katrincsáková B, Rozmanová S, Jarosová M, Indrák K, Adam T. Faber E, et al. Among authors: indrak k. Int J Hematol. 2010 Jun;91(5):897-902. doi: 10.1007/s12185-010-0576-y. Epub 2010 May 1. Int J Hematol. 2010. PMID: 20437122
Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy.
Rohon P, Divoka M, Calabkova L, Mojzikova R, Katrincsakova B, Rusinakova Z, Lapcikova A, Raida L, Faber E, Jarosova M, Divoky V, Indrak K. Rohon P, et al. Among authors: indrak k. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Jun;155(2):187-90. doi: 10.5507/bp.2011.030. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011. PMID: 21804629 Free article.
197 results